Drug Profile
Research programme: IKK-beta inhibitor - HUTCHMED
Alternative Names: HM-A42; HMPL-342Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Class
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma; Inflammation; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in China (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in China (PO)